Our biosimilars pipeline
We are committed to providing valued biologic treatments through the development of new immunology and oncology therapies in our expanding biosimilars portfolio.
Our pipeline includes biosimilars of adalimumab (Idacio® currently commercialized in 35 countries, Aug. 2022) and tocilizumab (MSB11456 – currently in development) in the autoimmune disease (immunology) therapy area, and a biosimilar of pegfilgrastim in the oncology therapy area.
In addition, we have multiple candidates in early-phase development, in both autoimmune and oncology therapy areas.
